Krystal Biotech Inc (KRYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.05B
Last updated: Nov 17, 2026 at 11:06 AM ET
Krystal Biotech Inc (KRYS) Financials: Revenue, Profit and Cash Flow
Krystal Biotech reported revenue of $389.13M for the fiscal year ended Dec 31, 2025, up 33.9% from the year before. That year, net income was $204.83M with a net margin of 52.6%, operating cash flow was $200.87M and free cash flow was $188.91M. The quarter ended Sep 30, 2026 had revenue of $127.34M and net income of $63.07M.
Revenue and Margins
The operating margin was 41.5% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $389.13M | +33.9% | 94.1% | 41.5% | 52.6% |
| Dec 2024 | $290.51M | +473.0% | 93.1% | 22.6% | 30.7% |
| Dec 2023 | $50.70M | N/A | 93.9% | -216.2% | 21.6% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income rose 129.7% from the year before. In the quarter ended Sep 2026, net income fell 20.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $23.05M | $20.06M | $3.09M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $366.08M | $270.45M | $47.60M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $58.05M | $53.58M | $46.43M | $42.46M | $27.88M | $17.94M | $15.62M | $7.76M | $3.21M | $741.00K |
| Operating income | $161.29M | $65.75M | -$109.62M | -$145.20M | -$68.28M | -$33.00M | -$22.08M | -$11.92M | -$4.77M | -$1.14M |
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | -$69.57M | -$32.17M | -$19.09M | -$10.89M | -$7.92M | -$1.15M |
| EBITDA | $167.85M | $72.46M | -$3.71M | -$141.81M | -$65.51M | -$30.32M | -$20.99M | -$10.75M | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $127.34M | $119.22M | $116.36M | $107.11M | $97.80M | $96.04M | $88.18M | $91.14M | $83.84M | $70.28M | $45.25M | $42.14M |
| Gross profit | $119.78M | $112.78M | $110.03M | $100.51M | $93.54M | $88.88M | $83.16M | $86.19M | $77.16M | $64.28M | $42.83M | $39.05M |
| Operating income | $71.14M | $58.42M | $53.69M | $44.44M | $41.37M | $39.40M | $36.25M | $41.39M | $22.47M | $8.57M | -$6.68M | $3.25M |
| Net income | $63.07M | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M | $35.73M | $45.48M | $27.18M | $15.57M | $932.00K | $8.69M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.77M by $494.53M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.33B | $1.06B | $818.36M | $558.45M | $626.29M | $310.84M | $209.02M | $116.12M | $50.11M | $2.18M |
| Current assets | $1.02B | $742.04M | $587.91M | $383.78M | $442.27M | $275.06M | $195.88M | $112.65M | $49.91M | $2.17M |
| Cash and equivalents | $496.30M | $344.87M | $358.33M | $161.90M | $341.25M | $268.27M | $187.51M | $103.67M | $49.59M | $1.92M |
| Total liabilities | $114.23M | $109.46M | $39.71M | $36.22M | $32.72M | $18.76M | $6.11M | $2.89M | $640.00K | $1.89M |
| Short-term debt | $1.77M | $1.22M | $1.47M | $1.56M | $1.04M | $8.24M | $480.00K | N/A | N/A | $0 |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $1.84M |
| Shareholder equity | $1.22B | $946.38M | $778.64M | $522.23M | $593.58M | $292.08M | $202.91M | $113.23M | $49.47M | $289.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.59B | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B | $1.06B | $982.32M | $917.66M | $853.30M | $818.36M |
| Total liabilities | $150.47M | $141.52M | $120.24M | $114.23M | $102.22M | $97.75M | $89.74M | $109.46M | $96.47M | $78.77M | $54.05M | $39.71M |
| Cash and equivalents | $462.84M | $427.74M | $501.31M | $496.30M | $392.60M | $353.83M | $308.77M | $344.87M | $373.97M | $345.79M | $359.01M | $358.33M |
| Shareholder equity | $1.44B | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | $984.67M | $946.38M | $885.85M | $838.89M | $799.24M | $778.64M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 94.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $200.87M | $123.42M | -$88.80M | -$100.57M | -$47.94M | -$26.08M | -$18.69M | -$9.45M | -$3.89M | -$1.31M |
| Capital expenditures | $11.95M | $4.24M | $11.80M | $52.98M | $68.34M | $14.84M | $6.40M | $2.23M | $210.00K | $15.00K |
| Free cash flow | $188.91M | $119.18M | -$100.60M | -$153.55M | -$116.27M | -$40.93M | -$25.09M | -$11.68M | -$4.10M | -$1.33M |
| Investing cash flow | -$58.42M | -$163.44M | $82.64M | -$114.08M | -$226.77M | -$11.18M | -$4.99M | -$10.32M | -$210.00K | -$15.00K |
| Financing cash flow | $8.71M | $27.01M | $202.75M | $35.35M | $347.69M | $118.02M | $107.53M | $73.85M | $51.77M | $3.25M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $91.25M | $74.79M | $80.38M | $77.51M | $39.66M | $52.73M | $30.97M | $52.84M | $58.86M | -$4.17M | $15.89M | -$7.23M |
| Capital expenditures | $996.00K | $3.56M | $7.15M | $2.14M | $1.70M | $1.90M | $6.20M | $801.00K | $1.05M | $1.13M | $1.26M | $1.85M |
| Free cash flow | $90.25M | $71.22M | $73.23M | $75.37M | $37.95M | $50.83M | $24.77M | $52.04M | $57.81M | -$5.30M | $14.63M | -$9.08M |
Frequently Asked Questions About KRYS
What is Krystal Biotech's annual revenue?
Krystal Biotech reported revenue of $389.13M for the fiscal year ended Dec 31, 2025.
How fast is Krystal Biotech's revenue growing?
Revenue was up 33.9% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Krystal Biotech profitable?
Yes. Krystal Biotech reported net income of $204.83M for the fiscal year ended Dec 31, 2025, with a net margin of 52.6%.
How much free cash flow does KRYS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $200.87M minus capital expenditures of $11.95M produced free cash flow of $188.91M.
How much debt does Krystal Biotech have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.77M and cash and equivalents of $496.30M.
KRYS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors